CoChat

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Background Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes. Methods We did a randomised, double-blind, parallel-group, placebo-controlled trial in 309 centres worldwide. We recruited normoalbuminuric, normotensive, or treated hypertensive people with type 2 diabetes with mild to moderately severe retinopathy and assigned them to candesartan 16 mg once a day or placebo. After a month, the dose was doubled to 32 mg once per day. Investigators and patients were unaware of the treatment allocation status. Progression of retinopathy was the primary endpoint, and regression was a secondary endpoint. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00252694. Findings 1905 participants (aged 37-75 years) were randomised to candesartan (n=951) or placebo (n=954). 161 (17%) patients in the candesartan group and 182 (19%) in the placebo group had progression of retinopathy by three steps or more on the Early Treatment Diabetic Retinopathy Study scale. The risk of progression of retinopathy was non-significantly reduced by 13% in patients on candesartan compared with those on placebo (hazard ratio [HR] 0.87, 95% CI 0.70-1.08, p=0.20). Regression on active treatment was increased by 34% (1.34, 1.08-1.68, p=0.009). HRs were not attenuated by adjustment for basel…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)61411-7

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. O'Brien RG, Castelloe J. Exploiting the link between the Wilcoxon-Mann-Whitney test and a simple odds statistic. Proceedings of the Thirty-first Annual SAS Users Group International Conference. Cary, NC, USA: SAS Institute, USA. http://www2.sas.com/proceedings/sugi31/209-31.pdf (accessed Jan 27, 2008).

Cited by

See all 435

Metadata

Authors
Sjølie, A. K., Klein, R., Porta, M., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Chaturvedi, N.
Affiliations
  • Odense University Hospital (DK)
  • University of Wisconsin–Madison (US)
  • University of Turin (IT)
  • University of Pittsburgh (US)
  • University College London (GB)
  • Copenhagen University Hospital (DK)
  • Imperial College Healthcare NHS Trust (GB)
Venue
The Lancet
Publisher
Elsevier BV
Published
2008-10
Volume
372
Issue
9647
Pages
1385-1393
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2109689720
Cited by
435
References
52
Citations by year
2026: 6 · 2025: 9 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 10 · 2020: 14 · 2019: 15 · 2018: 24 · 2017: 25 · 2016: 26 · 2015: 26 · 2014: 37 · 2013: 30 · 2012: 44
FWCI
45.84
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
  • Griffith Research Online (submittedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
Keywords
candesartan, diabetic retinopathy, type 2 diabetes, retinopathy progression, retinopathy regression, angiotensin receptor blockers, blindness prevention, blood pressure, adverse events, normoalbuminuria, hypertension, normotension, dose escalation, treatment discontinuation, retinopathy screening
MeSH terms
Adult, Aged, Benzimidazoles, Biphenyl Compounds, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Severity of Illness Index, Tetrazoles, Endpoint Determination, Angiotensin II Type 1 Receptor Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(08)61411-7
The paper
Sjølie, A. K., Klein, R., Porta, M., Orchard, T., Fuller, J., Parving, H. H., Bilous, R., & Chaturvedi, N. (2008). Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(08)61411-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.